We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
APR Acquires Drug Delivery Nanotechnology Platform Providing Treatments for Critical Diseases
News

APR Acquires Drug Delivery Nanotechnology Platform Providing Treatments for Critical Diseases

APR Acquires Drug Delivery Nanotechnology Platform Providing Treatments for Critical Diseases
News

APR Acquires Drug Delivery Nanotechnology Platform Providing Treatments for Critical Diseases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "APR Acquires Drug Delivery Nanotechnology Platform Providing Treatments for Critical Diseases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

APR Applied Pharma Research s.a. announces the acquisition of a new platform technology consisting of a patented Nanocoating process for the preparation of new patent protected biotechnology products for the treatment of several critical diseases in multiple therapeutic areas. APR is already developing specific applications of the resulting products in ophthalmology and dermatology. Financial terms of the acquisition were not disclosed.

“We decided to acquire this new platform technology when we understood the great potential of combining a process based on nano-coating technology to totally biological compounds to obtain products with powerful healing capabilities and minimal side effects or tolerability issues” – said Paolo Galfetti, CEO of APR - “The products based on this new technology may unlock new therapeutic solutions to unmet needs in several critical therapeutic areas”.

APR has first targeted the treatment of eye injuries, including cataract, chronic and acute infected wounds, including surgically induced wounds and skin and eye infections, where initial tests made with the first product derived from the new technology showed most promising results. Several other applications of this technology are also being studied.

APR has already performed several “in vitro” and “in vivo” pre-clinical tests studying the critical features of the first product obtained with the nano-coating patented process, including its chemical analysis, stability, toxicology, safety and efficacy with positive and promising results. Also a Phase II study in surgically induced wounds has been performed with excellent results: APR is now ready to enter the first clinical studies in eye wound and cataract healing.

“In order to give the right focus to this new important step in the expansion of APR R&D portfolio as well as to give the Inventors of this technology platform a substantial stake into this venture, APR decided to create a new company specifically dedicated to the development of this and possible future applications of our nanotechnology. This new company, named “APR Nanotechnologies s.a.”, will also be headquartered in Switzerland and will be based in Balerna” – concluded Paolo Galfetti.
Advertisement